GSK 1536489A

Drug Profile

GSK 1536489A

Alternative Names: FluLaval; FluLaval trivalent; FluLaval-YB; FluSF; Fluviral; Fluviral-S-F; Fluviral-S/F; GSK-1536489A; GSK-1557482A; Influenza vaccine split virion inactivated - GlaxoSmithKline; SPD-707

Latest Information Update: 30 Mar 2016

Price : $50

At a glance

  • Originator ID Biomedical Corporation
  • Developer Folia Biotech; GlaxoSmithKline; ID Biomedical Corporation; Pan-Provincial Vaccine Enterprise
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 01 Apr 2014 Phase-I clinical trials in Influenza virus infections (adjuvant therapy, prevention) in Canada (IM)
  • 19 Aug 2013 US FDA expands approval of FluLaval® for use in children aged 3 years and older, and adults in USA
  • 01 Aug 2013 GlaxoSmithKline completes a phase III trial for Influenza virus infections (2013-2014 season) in Canada (IM) (NCT01878825)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top